A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients
Identifieur interne : 000E36 ( Main/Exploration ); précédent : 000E35; suivant : 000E37A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients
Auteurs : Lihua Zhu [République populaire de Chine] ; Lingling Zhou [République populaire de Chine] ; Liang Wang [République populaire de Chine] ; Zhaoxia Li [République populaire de Chine] ; Shuai Lu [République populaire de Chine] ; Lijian Yang [République populaire de Chine] ; Shaohua Chen [République populaire de Chine] ; Bo Li [République populaire de Chine] ; Xiuli Wu [République populaire de Chine] ; Yi Zhou [République populaire de Chine] ; Yangqiu Li [République populaire de Chine]Source :
- Asia‐Pacific Journal of Clinical Oncology [ 1743-7555 ] ; 2016-12.
Abstract
Aim: An increased risk for malignancy for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients may be related to factors that play a critical role in the regulation of T‐cell activation. A20 is an important negative immunoregulatory factor that was found to be associated with lymphoma and the development of numerous solid tumors. Previous studies have implicated the A20 locus in RA susceptibility. In this study, we investigated polymorphisms in the A20 3′ UTR and explored whether there was an association between these polymorphisms and malignancy risk in autoimmune diseases. Methods: PCR and sequencing were used to identify A20 gene polymorphisms in peripheral blood mononuclear cells (PBMCs) from 99 RA cases, 37 SLE cases and 99 healthy individuals. Pearson's Chi square test was used for statistical analysis. Results: Only one SNP (rs77191406) and one new mutation (20132 A>G) in A20 gene were identified in RA and SLE patients and healthy individuals. Heterozygous rs77191406 was identified in just 1 of 99 RA patients and 2 of 37 SLE patients. More importantly, a RA patient who was heterozygous for rs77191406 developed colon cancer 10 years after the RA diagnosis. Similarly, two SLE patients carrying rs77191406 (heterozygous) had severe disease or developed bladder cancer 5 years after SLE diagnosis. Conclusions: These findings suggest that rs77191406 may be a prognostic marker for a high risk for rapid malignancy progression, poor survival and refractory disease and a new molecular marker associated with autoimmune diseases transforming into a secondary cancer.
Url:
DOI: 10.1111/ajco.12577
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B89
- to stream Istex, to step Curation: 000B89
- to stream Istex, to step Checkpoint: 000055
- to stream Main, to step Merge: 000E37
- to stream Main, to step Curation: 000E36
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients</title><author><name sortKey="Zhu, Lihua" sort="Zhu, Lihua" uniqKey="Zhu L" first="Lihua" last="Zhu">Lihua Zhu</name></author><author><name sortKey="Zhou, Lingling" sort="Zhou, Lingling" uniqKey="Zhou L" first="Lingling" last="Zhou">Lingling Zhou</name></author><author><name sortKey="Wang, Liang" sort="Wang, Liang" uniqKey="Wang L" first="Liang" last="Wang">Liang Wang</name></author><author><name sortKey="Li, Zhaoxia" sort="Li, Zhaoxia" uniqKey="Li Z" first="Zhaoxia" last="Li">Zhaoxia Li</name></author><author><name sortKey="Lu, Shuai" sort="Lu, Shuai" uniqKey="Lu S" first="Shuai" last="Lu">Shuai Lu</name></author><author><name sortKey="Yang, Lijian" sort="Yang, Lijian" uniqKey="Yang L" first="Lijian" last="Yang">Lijian Yang</name></author><author><name sortKey="Chen, Shaohua" sort="Chen, Shaohua" uniqKey="Chen S" first="Shaohua" last="Chen">Shaohua Chen</name></author><author><name sortKey="Li, Bo" sort="Li, Bo" uniqKey="Li B" first="Bo" last="Li">Bo Li</name></author><author><name sortKey="Wu, Xiuli" sort="Wu, Xiuli" uniqKey="Wu X" first="Xiuli" last="Wu">Xiuli Wu</name></author><author><name sortKey="Zhou, Yi" sort="Zhou, Yi" uniqKey="Zhou Y" first="Yi" last="Zhou">Yi Zhou</name></author><author><name sortKey="Li, Yangqiu" sort="Li, Yangqiu" uniqKey="Li Y" first="Yangqiu" last="Li">Yangqiu Li</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CF8957306DCEA54B084ACDB0F3DCF5E973385EFA</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/ajco.12577</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-6864GF6H-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B89</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B89</idno><idno type="wicri:Area/Istex/Curation">000B89</idno><idno type="wicri:Area/Istex/Checkpoint">000055</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000055</idno><idno type="wicri:doubleKey">1743-7555:2016:Zhu L:a:snp:rs</idno><idno type="wicri:Area/Main/Merge">000E37</idno><idno type="wicri:Area/Main/Curation">000E36</idno><idno type="wicri:Area/Main/Exploration">000E36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients</title><author><name sortKey="Zhu, Lihua" sort="Zhu, Lihua" uniqKey="Zhu L" first="Lihua" last="Zhu">Lihua Zhu</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Rheumatism and Immunology, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Zhou, Lingling" sort="Zhou, Lingling" uniqKey="Zhou L" first="Lingling" last="Zhou">Lingling Zhou</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory for Regenerative Medicine of Ministry of Education, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Wang, Liang" sort="Wang, Liang" uniqKey="Wang L" first="Liang" last="Wang">Liang Wang</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Oncology, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Li, Zhaoxia" sort="Li, Zhaoxia" uniqKey="Li Z" first="Zhaoxia" last="Li">Zhaoxia Li</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Rheumatism and Immunology, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Lu, Shuai" sort="Lu, Shuai" uniqKey="Lu S" first="Shuai" last="Lu">Shuai Lu</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory for Regenerative Medicine of Ministry of Education, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Yang, Lijian" sort="Yang, Lijian" uniqKey="Yang L" first="Lijian" last="Yang">Lijian Yang</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Chen, Shaohua" sort="Chen, Shaohua" uniqKey="Chen S" first="Shaohua" last="Chen">Shaohua Chen</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Li, Bo" sort="Li, Bo" uniqKey="Li B" first="Bo" last="Li">Bo Li</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Wu, Xiuli" sort="Wu, Xiuli" uniqKey="Wu X" first="Xiuli" last="Wu">Xiuli Wu</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Zhou, Yi" sort="Zhou, Yi" uniqKey="Zhou Y" first="Yi" last="Zhou">Yi Zhou</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Rheumatism and Immunology, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Li, Yangqiu" sort="Li, Yangqiu" uniqKey="Li Y" first="Yangqiu" last="Li">Yangqiu Li</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Hematology, Medical College, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory for Regenerative Medicine of Ministry of Education, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Departments of Hematology, First Affiliated Hospital, Jinan University, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation><affiliation></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Asia‐Pacific Journal of Clinical Oncology</title><title level="j" type="alt">ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY</title><idno type="ISSN">1743-7555</idno><idno type="eISSN">1743-7563</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="409">409</biblScope><biblScope unit="page" to="414">414</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-12">2016-12</date></imprint><idno type="ISSN">1743-7555</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1743-7555</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Aim: An increased risk for malignancy for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients may be related to factors that play a critical role in the regulation of T‐cell activation. A20 is an important negative immunoregulatory factor that was found to be associated with lymphoma and the development of numerous solid tumors. Previous studies have implicated the A20 locus in RA susceptibility. In this study, we investigated polymorphisms in the A20 3′ UTR and explored whether there was an association between these polymorphisms and malignancy risk in autoimmune diseases. Methods: PCR and sequencing were used to identify A20 gene polymorphisms in peripheral blood mononuclear cells (PBMCs) from 99 RA cases, 37 SLE cases and 99 healthy individuals. Pearson's Chi square test was used for statistical analysis. Results: Only one SNP (rs77191406) and one new mutation (20132 A>G) in A20 gene were identified in RA and SLE patients and healthy individuals. Heterozygous rs77191406 was identified in just 1 of 99 RA patients and 2 of 37 SLE patients. More importantly, a RA patient who was heterozygous for rs77191406 developed colon cancer 10 years after the RA diagnosis. Similarly, two SLE patients carrying rs77191406 (heterozygous) had severe disease or developed bladder cancer 5 years after SLE diagnosis. Conclusions: These findings suggest that rs77191406 may be a prognostic marker for a high risk for rapid malignancy progression, poor survival and refractory disease and a new molecular marker associated with autoimmune diseases transforming into a secondary cancer.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Guangdong</li></region><settlement><li>Jiangmen</li></settlement></list><tree><country name="République populaire de Chine"><region name="Guangdong"><name sortKey="Zhu, Lihua" sort="Zhu, Lihua" uniqKey="Zhu L" first="Lihua" last="Zhu">Lihua Zhu</name></region><name sortKey="Chen, Shaohua" sort="Chen, Shaohua" uniqKey="Chen S" first="Shaohua" last="Chen">Shaohua Chen</name><name sortKey="Li, Bo" sort="Li, Bo" uniqKey="Li B" first="Bo" last="Li">Bo Li</name><name sortKey="Li, Yangqiu" sort="Li, Yangqiu" uniqKey="Li Y" first="Yangqiu" last="Li">Yangqiu Li</name><name sortKey="Li, Yangqiu" sort="Li, Yangqiu" uniqKey="Li Y" first="Yangqiu" last="Li">Yangqiu Li</name><name sortKey="Li, Yangqiu" sort="Li, Yangqiu" uniqKey="Li Y" first="Yangqiu" last="Li">Yangqiu Li</name><name sortKey="Li, Zhaoxia" sort="Li, Zhaoxia" uniqKey="Li Z" first="Zhaoxia" last="Li">Zhaoxia Li</name><name sortKey="Li, Zhaoxia" sort="Li, Zhaoxia" uniqKey="Li Z" first="Zhaoxia" last="Li">Zhaoxia Li</name><name sortKey="Lu, Shuai" sort="Lu, Shuai" uniqKey="Lu S" first="Shuai" last="Lu">Shuai Lu</name><name sortKey="Lu, Shuai" sort="Lu, Shuai" uniqKey="Lu S" first="Shuai" last="Lu">Shuai Lu</name><name sortKey="Wang, Liang" sort="Wang, Liang" uniqKey="Wang L" first="Liang" last="Wang">Liang Wang</name><name sortKey="Wu, Xiuli" sort="Wu, Xiuli" uniqKey="Wu X" first="Xiuli" last="Wu">Xiuli Wu</name><name sortKey="Yang, Lijian" sort="Yang, Lijian" uniqKey="Yang L" first="Lijian" last="Yang">Lijian Yang</name><name sortKey="Zhou, Lingling" sort="Zhou, Lingling" uniqKey="Zhou L" first="Lingling" last="Zhou">Lingling Zhou</name><name sortKey="Zhou, Lingling" sort="Zhou, Lingling" uniqKey="Zhou L" first="Lingling" last="Zhou">Lingling Zhou</name><name sortKey="Zhou, Yi" sort="Zhou, Yi" uniqKey="Zhou Y" first="Yi" last="Zhou">Yi Zhou</name><name sortKey="Zhu, Lihua" sort="Zhu, Lihua" uniqKey="Zhu L" first="Lihua" last="Zhu">Lihua Zhu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CF8957306DCEA54B084ACDB0F3DCF5E973385EFA
|texte= A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients
}}
| This area was generated with Dilib version V0.6.33. |  |